PhRMA Statement on New Strategic Plan from the IP Enforcement Coordinator

PhRMA Statement on New Strategic Plan from the IP Enforcement Coordinator

WASHINGTON, D.C. (June 19, 2013) – Pharmaceutical Research and Manufacturers of America International Senior Vice President Rod Hunter issued the following statement today on the release of the second Joint Strategic Plan from the Intellectual Property Enforcement Coordinator (IPEC) Victoria Espinel:

“While intellectual property infringement threatens the ideas and innovations that are the lifeblood of pharmaceutical companies and, in turn, our industry’s contribution to the U.S. economy, it also presents a very real public health and safety danger to patients world-wide.

“We are pleased that the IPEC report recognizes the need to develop a concrete agenda to battle intellectual property infringement.  We applaud the focus on robust enforcement of IP rights worldwide, in particular through the interagency working group on counterfeit pharmaceuticals and foreign counterpart coordination and training.   We support the plan’s goal of enhancing U.S. advocacy on IP issues in multiple international fora and through trade policy.

“ We are heartened to see that IPEC’s plan prioritizes initiatives to protect patients in the United States and around the world from the threat of fake drugs..  We are reviewing the plan’s specific recommendations designed to strengthen the prescription drug supply chain, and look forward to ongoing dialogue with Government stakeholders and others on these and other various mechanisms to combat the scourge of fake medicines worldwide. 

“As IPEC continues its work, we encourage the Administration to use every opportunity to ensure that countries such as India respect, protect, and enforce intellectual property rights.  Doing so is critical to the important advances that IP-intensive U.S. industries are making around the world.”


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org

More On PhRMA — powered by PhRMApedia